Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in:

Open Access 01-12-2024 | Research

Constructing and identifying an eighteen-gene tumor microenvironment prognostic model for non-small cell lung cancer

Authors: Zaishan Li, Zhenzhen Meng, Lin Xiao, Jiahui Du, Dazhi Jiang, Baoling Liu

Published in: World Journal of Surgical Oncology | Issue 1/2024

Login to get access

Abstract

Background

The tumor microenvironment (TME) plays a crucial role in tumorigenesis and tumor progression. This study aimed to identify novel TME-related biomarkers and develop a prognostic model for patients with non-small-cell lung cancer (NSCLC).

Methods

After downloading and preprocessing data from The Cancer Genome Atlas (TCGA) data portal and Gene Expression Omnibus (GEO) datasets, we classified the molecular subtypes using the “NMF” R package. We performed survival analysis and quantified immune scores between clusters. A Cox proportional hazards model was then constructed, and its formula was produced. We assessed model performance and clinical utility. A prediction nomogram was also constructed and validated. Additionally, we explored the potential regulatory mechanisms of our TME gene signature using Gene Set Enrichment Analysis (GSEA).

Results

From data processing and univariate Cox regression analysis, 57 TME-related prognostic genes were identified, and two significantly distinct clusters were established. Using Cox regression and Lasso regression, an 18-gene TME-related prognostic model was developed. Patients were stratified into high- and low-risk groups based on the risk score, with survival analysis showing that the low-risk group had significantly better outcomes than the high-risk group (P < 0.01). ROC curve analysis demonstrated strong predictive performance, with 1-year, 3-year, and 5-year AUC values ranging from 0.654 to 0.702 across different cohorts. The model accurately predicted survival outcomes across subgroups with varying clinical features, and its predictive accuracy was validated through a nomogram.

Conclusions

We developed a prognostic model based on TME-related genes in NSCLC. Our 18-gene TME signature can effectively predict the prognosis of NSCLC with high accuracy.
Appendix
Available only for authorised users
Literature
1.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.PubMedCrossRef
2.
Tan X, Tong L, Li L, et al. Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation. Nat Commun. 2021;12:4853.PubMedPubMedCentralCrossRef
3.
Zhan P, Zhang B, Xi GM, et al. PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/beta-catenin signaling pathway. Mol Cancer. 2017;16:108.PubMedPubMedCentralCrossRef
4.
Li B, Zhu L, Lu C, et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021;12:295.PubMedPubMedCentralCrossRef
5.
Haratani K, Hayashi H, Chiba Y, et al. Association of Immune-related adverse events with Nivolumab Efficacy in Non-small-cell Lung Cancer. JAMA Oncol. 2018;4:374–8.PubMedCrossRef
6.
Gettinger SN, Horn L, Gandhi L, et al. Overall survival and Long-Term Safety of Nivolumab (Anti-programmed Death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated Advanced Non-small-cell Lung Cancer. J Clin Oncol. 2015;33:2004–12.PubMedPubMedCentralCrossRef
7.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus Docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.PubMedCrossRef
8.
Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive non-small-cell Lung Cancer. N Engl J Med. 2016;375:1823–33.PubMedCrossRef
9.
Li C, Pan J, Luo J, Chen X. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy. BMC Pulm Med. 2021;21:389.PubMedPubMedCentralCrossRef
10.
Nabet BY, Hamidi H, Lee MC, et al. Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024;42:429–e443424.PubMedCrossRef
11.
Wang Q, Li M, Yang M, et al. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy. Aging. 2020;12:3312–39.PubMedPubMedCentralCrossRef
12.
Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353–65.PubMedCrossRef
13.
14.
Seebacher NA, Krchniakova M, Stacy AE, et al. Tumour Microenvironment stress promotes the development of Drug Resistance. Antioxidants (Basel; 2021. p. 10.
15.
16.
Lee SS, Cheah YK. (2019) The Interplay between MicroRNAs and Cellular Components of Tumour Microenvironment (TME) on Non-Small-Cell Lung Cancer (NSCLC) Progression. J Immunol Res 2019:3046379.
17.
Kang JH, Zappasodi R. Modulating Treg stability to improve cancer immunotherapy. Trends Cancer. 2023;9:911–27.PubMedCrossRef
18.
Yu H, Liu J, Bu X, et al. Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy. Cell Chem Biol. 2024;31:776–91. e777.PubMedCrossRef
19.
Liu L, Li S, Qu Y, et al. Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. Cell Rep Med. 2023;4:101206.PubMedPubMedCentralCrossRef
20.
Zheng M, Long J, Chelariu-Raicu A et al. (2021) Identification of a Novel Tumor Microenvironment Prognostic signature for Advanced-Stage Serous Ovarian Cancer. Cancers (Basel) 13.
21.
Sarkar K, Chowdhury R, Dasgupta A. Analysis of Survival Data: challenges and Algorithm-based model selection. J Clin Diagn Res. 2017;11:LC14–20.PubMedPubMedCentral
22.
23.
Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218.PubMedPubMedCentralCrossRef
24.
Woolston A, Khan K, Spain G, et al. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell. 2019;36:35–50. e39.PubMedPubMedCentralCrossRef
25.
Wu Y, Fu L, Wang B, et al. Construction of a prognostic risk assessment model for lung adenocarcinoma based on integrin beta family-related genes. J Clin Lab Anal. 2022;36:e24419.PubMedPubMedCentralCrossRef
26.
Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 2020;11:3475.PubMedPubMedCentralCrossRef
27.
Christiaens A, Boland B, Germanidis M, et al. Poor health status, inappropriate glucose-lowering therapy and high one-year mortality in geriatric patients with type 2 diabetes. BMC Geriatr. 2020;20:367.PubMedPubMedCentralCrossRef
28.
29.
Luo Y, Zhang G. Identification of a Necroptosis-Related Prognostic Index and Associated Regulatory Axis in kidney renal clear cell carcinoma. Int J Gen Med. 2022;15:5407–23.PubMedPubMedCentralCrossRef
30.
Cao X, He J, Chen A et al. (2023) Comprehensive Analysis of Necroptosis Landscape in skin cutaneous melanoma for appealing its implications in Prognosis Estimation and Microenvironment Status. J Pers Med 13.
31.
Tao S, Tao K, Cai X. (2022) Necroptosis-Associated lncRNA Prognostic Model and Clustering Analysis: Prognosis Prediction and Tumor-Infiltrating Lymphocytes in Breast Cancer. J Oncol 2022:7099930.
32.
Zheng M, Mullikin H, Hester A et al. (2020) Development and validation of a Novel 11-Gene prognostic model for Serous Ovarian Carcinomas based on lipid metabolism expression Profile. Int J Mol Sci 21.
33.
Liu Y, Wang L, Fang L, et al. A Multi-center Validated Subtyping Model of Esophageal Cancer based on three metabolism-related genes. Front Oncol. 2021;11:772145.PubMedPubMedCentralCrossRef
34.
Shi D, Mu S, Pu F, et al. Integrative analysis of immune-related multi-omics profiles identifies distinct prognosis and tumor microenvironment patterns in osteosarcoma. Mol Oncol. 2022;16:2174–94.PubMedPubMedCentralCrossRef
35.
Ferrone CR, Kattan MW, Tomlinson JS, et al. Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol. 2005;23:7529–35.PubMedCrossRef
36.
Ma C, Luo H, Cao J, et al. Identification of a Novel Tumor Microenvironment-Associated eight-gene signature for Prognosis Prediction in Lung Adenocarcinoma. Front Mol Biosci. 2020;7:571641.PubMedPubMedCentralCrossRef
37.
Zhang X, Shi X, Zhao H et al. (2021) Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer. Biomed Res Int 2021:8864436.
38.
Sun S, Guo W, Wang Z, et al. Development and validation of an immune-related prognostic signature in lung adenocarcinoma. Cancer Med. 2020;9:5960–75.PubMedPubMedCentralCrossRef
39.
Song C, Guo Z, Yu D, et al. A prognostic Nomogram Combining Immune-related gene signature and clinical factors predicts survival in patients with lung adenocarcinoma. Front Oncol. 2020;10:1300.PubMedPubMedCentralCrossRef
40.
Gopal RK, Kubler K, Calvo SE, et al. Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hurthle Cell Carcinoma. Cancer Cell. 2018;34:242–e255245.PubMedPubMedCentralCrossRef
41.
Wagner AH, Devarakonda S, Skidmore ZL, et al. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nat Commun. 2018;9:3787.PubMedPubMedCentralCrossRef
42.
Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29:2046–51.PubMedPubMedCentralCrossRef
43.
Dziadziuszko R, Krebs MG, De Braud F, et al. Updated Integrated Analysis of the efficacy and safety of Entrectinib in locally Advanced or Metastatic ROS1 Fusion-positive non-small-cell Lung Cancer. J Clin Oncol. 2021;39:1253–63.PubMedPubMedCentralCrossRef
44.
Li BT, Michelini F, Misale S, et al. HER2-Mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov. 2020;10:674–87.PubMedPubMedCentralCrossRef
45.
Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011;1:78–89.PubMedPubMedCentralCrossRef
46.
Gautschi O, Milia J, Filleron T, et al. Targeting RET in patients with RET-Rearranged lung cancers: results from the Global, Multicenter RET Registry. J Clin Oncol. 2017;35:1403–10.PubMedPubMedCentralCrossRef
47.
Junnila S, Kokkola A, Karjalainen-Lindsberg ML, et al. Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. BMC Cancer. 2010;10:73.PubMedPubMedCentralCrossRef
48.
Sumita Y, Yamazaki M, Maruyama S, et al. Cytoplasmic expression of SOX9 as a poor prognostic factor for oral squamous cell carcinoma. Oncol Rep. 2018;40:2487–96.PubMedPubMedCentral
49.
Higo N, Okumura H, Uchikado Y, et al. Expression of SOX9 is related to prognosis in patients with oesophageal squamous cell carcinoma. Vivo. 2018;32:835–8.CrossRef
50.
Mahtab M, Boavida A, Santos D, Pisani FM. (2021) The Genome Stability maintenance DNA helicase DDX11 and its role in Cancer. Genes (Basel) 12.
51.
Avgustinova A, Iravani M, Robertson D, et al. Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. Nat Commun. 2016;7:10305.PubMedPubMedCentralCrossRef
52.
53.
Zhang Y, Yang J, Wang X, Li X. GNG7 and ADCY1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma through bioinformatic-based analyses. Sci Rep. 2021;11:20441.PubMedPubMedCentralCrossRef
54.
Kalathil D, John S, Nair AS. FOXM1 and Cancer: Faulty Cellular Signaling derails Homeostasis. Front Oncol. 2020;10:626836.PubMedCrossRef
55.
Dabi Y, Willecocq C, Ballester M, et al. Identification of a low risk population for parametrial invasion in patients with early-stage cervical cancer. J Transl Med. 2018;16:163.PubMedPubMedCentralCrossRef
56.
Hu SP, Chen L, Lin CY, et al. The Prognostic Value of Preoperative Geriatric Nutritional Risk Index in patients with pancreatic ductal adenocarcinoma. Cancer Manag Res. 2020;12:385–95.PubMedPubMedCentralCrossRef
57.
He Y, Mao M, Shi W, et al. Development and validation of a prognostic nomogram in gastric cancer with hepatitis B virus infection. J Transl Med. 2019;17:98.PubMedPubMedCentralCrossRef
58.
Chen D, Liu Z, Liu W, et al. Predicting postoperative peritoneal metastasis in gastric cancer with serosal invasion using a collagen nomogram. Nat Commun. 2021;12:179.PubMedPubMedCentralCrossRef
59.
Niu X, Yang Y, Zhou X, et al. A prognostic nomogram for patients with newly diagnosed adult thalamic glioma in a surgical cohort. Neuro Oncol. 2021;23:337–8.PubMedCrossRef
60.
Zhang Z, Wang Z, Yan M, et al. Radiomics and Dosiomics signature from whole lung predicts Radiation Pneumonitis: a Model Development Study with prospective external validation and decision-curve analysis. Int J Radiat Oncol Biol Phys. 2023;115:746–58.PubMedCrossRef
61.
Hailemeskel HS, Tiruneh SA. Development of a Nomogram for Clinical Risk Prediction of Preterm Neonate Death in Ethiopia. Front Pediatr. 2022;10:877200.PubMedPubMedCentralCrossRef
62.
63.
64.
Simiczyjew A, Dratkiewicz E, Mazurkiewicz J et al. (2020) The influence of Tumor Microenvironment on Immune escape of Melanoma. Int J Mol Sci 21.
65.
Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23:660–70.PubMedPubMedCentralCrossRef
Metadata
Title
Constructing and identifying an eighteen-gene tumor microenvironment prognostic model for non-small cell lung cancer
Authors
Zaishan Li
Zhenzhen Meng
Lin Xiao
Jiahui Du
Dazhi Jiang
Baoling Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2024
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-024-03588-y

Other articles of this Issue 1/2024

Laparoscopic versus open gastrectomy for nonmetastatic T4a gastric cancer: a meta-analysis of reconstructed individual participant data from propensity score-matched studies

Textbook oncologic outcomes are associated with increased overall survival in patients with pancreatic head cancer after undergoing laparoscopic pancreaticoduodenectomy

  • Open Access
  • Research

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors

Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma

Clinical evaluation of oxaliplatin-loaded drug-eluting callispheres beads transarterial chemoembolization for unresectable or recurrent esophageal carcinoma

  • Open Access
  • Research

The clinical significance of elastic lamina invasion in patients with pStage II colorectal cancer: a notable prognostic indicator

SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

  • Webinar | 06-02-2024 | 20:00 (CET)

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now
Image Credits